
Life sciences companies benefit from the ‘pharma carveout’ in Trump’s tariffs. But how long will it last?
The exemption raised as many questions as it answered for drug makers clustered in Cambridge’s Kendall Square and other biopharma hubs in the Boston area. The carveout came as the administration imposed a universal baseline tariff of 10 percent, with China …